Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
Bello Roufai, D, Gonçalves, A, De La Motte Rouge, T, Akla, S, Blonz, C, Grenier, J, Gligorov, J, Saghatchian, M, Bailleux, C, Simon, H, Desmoulins, I, Tharin, Z, Renaud, E, Bertho, M, Benderra, M-A, Delaloge, S, Robert, L, Cottu, P, Pierga, J Y, Loirat, D, Bertucci, A, Renouf, B, Bidard, F C, Lerebours, F
Published in Oncogene (01.04.2023)
Published in Oncogene (01.04.2023)
Get full text
Journal Article
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
Bello Roufai, D, Gonçalves, A, De La Motte Rouge, T, Akla, S, Blonz, C, Grenier, J, Gligorov, J, Saghatchian, M, Bailleux, C, Simon, H, Desmoulins, I, Tharin, Z, Renaud, E, Bertho, M, Benderra, M-A, Delaloge, S, Robert, L, Cottu, P, Pierga, J Y, Loirat, D, Bertucci, A, Renouf, B, Bidard, F C, Lerebours, F
Published in Oncogene (06.06.2023)
Published in Oncogene (06.06.2023)
Get full text
Journal Article
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer
Kaderbhaï, C.-G., Coudert, B., Bertaut, A., Adnet, J., Favier, L., Lagrange, A., Peignaux-Casasnovas, K., Mettey, L., Tharin, Z., Foucher, P., Martin, E.
Published in Cancer radiothérapie (01.07.2020)
Published in Cancer radiothérapie (01.07.2020)
Get full text
Journal Article